Psychemedics (PMD) Stock Price, News & Analysis

Company Overview

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $2.33 to $2.34
• 50-Day Range: $2.30 to $2.36
• 52-Week Range: $1.63 to $3.93
• Volume: 27,871 shs
• Average Volume: 26,172 shs
• Market Capitalization: $13.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Psychemedics Stock Analysis - MarketRank™

Psychemedics scored higher than 17% of companies evaluated by MarketBeat, and ranked 888th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Psychemedics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Psychemedics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Psychemedics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Psychemedics has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of Psychemedics has been sold short.

Short Interest Ratio / Days to Cover

Psychemedics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psychemedics has recently decreased by 43.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Psychemedics does not currently pay a dividend.

Dividend Growth

Psychemedics has only been increasing its dividend for 1 years.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.31% of the float of Psychemedics has been sold short.

Short Interest Ratio / Days to Cover

Psychemedics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psychemedics has recently decreased by 43.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.07

News Sentiment

Psychemedics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Psychemedics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for PMD on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Psychemedics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.96% of the stock of Psychemedics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 32.07% of the stock of Psychemedics is held by institutions.

PMD Stock Analysis - Frequently Asked Questions

How have PMD shares performed this year?

Psychemedics' stock was trading at $2.96 at the start of the year. Since then, PMD shares have decreased by 21.3% and is now trading at $2.33.
View the best growth stocks for 2024 here.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings data on Tuesday, April, 23rd. The company reported $0.11 EPS for the quarter. The business had revenue of $9.82 million for the quarter. Psychemedics had a negative net margin of 14.59% and a negative trailing twelve-month return on equity of 49.05%.

How do I buy shares of Psychemedics?

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD).

Company Calendar

• Last Earnings: 4/23/2019
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PMD
• CUSIP: N/A
• CIK: 806517
• Web: www.psychemedics.com
• Phone: (978) 206-8220
• Fax: 978-264-9236
• Employees: 140
• Year Founded: 1985

Profitability

• EPS (Most Recent Fiscal Year): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,150,000.00
• Net Margins: -14.59%
• Pretax Margin: -14.55%
• Return on Equity: -49.05%
• Return on Assets: -27.26%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.59
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $20.26 million
• Price / Sales: 0.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 2.53

Miscellaneous

• Outstanding Shares: 5,894,000
• Free Float: 5,071,000
• Market Cap: $13.73 million
• Optionable: Not Optionable
• Beta: 0.65